The antivirion activity of streptovaricin complex against Friend virus varies significantly between lots and does not correlate with acute toxicity, suggesting the active component is not the major molecular structure.
Answers are grounded in this paper and cite their sources.
Lot variability in streptovaricin activity cautions against assuming uniform efficacy in retroviral models; leaves open identification of the active component.
The in vitro antivirion activities of five different streptovaricin complex lots against the polycythemic strain of the Friend virus were evaluated. The assay system was based on the inhibition of the Friend virus-induced spleen foci. The virus inactivation process was shown to be susceptible to variation in temperature, pH, and time. The antivirion activity and the acute toxicity for mice, as well as the optical properties of these streptovaricin complexes, do not co-vary; this suggests that their biological activities are not associated with a single molecular structure. In addition, the antivirion activity of the five preparations of streptovaricin complex differs about 30-fold, indicating that this activity does not reside in a major component of the complex.
No takes yet. Share an insight, caveat, or question.
Horoszewicz et al. (1974) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: